|1.||Munster, Pamela N: 2 articles (11/2011 - 04/2009)|
|2.||Daud, Adil I: 2 articles (11/2011 - 04/2009)|
|3.||DeConti, Ronald C: 1 article (04/2009)|
|4.||Bastien, Sem: 1 article (04/2009)|
|5.||Neuger, Anthony: 1 article (04/2009)|
|6.||Hausheer, Frederick A: 1 article (04/2009)|
|7.||Lush, Richard: 1 article (04/2009)|
|8.||Dawson, Jana: 1 article (04/2009)|
|9.||Bicaku, Elona: 1 article (04/2009)|
|10.||Sullivan, Daniel M: 1 article (04/2009)|
05/01/2008 - "Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study."
04/01/2008 - "Karenitecin and mafosfamide are additive or synergistic in vitro against tumor types that disseminate to the leptomeninges. "
07/01/2001 - "This study was designed to test the efficacy of karenitecin, a novel highly lipophilic camptothecin derivative, against a panel of human tumor xenografts derived from adult and pediatric central nervous system malignancies growing in athymic nude mice. "
09/01/2003 - "Artificial plasma, spiked with karenitecin, was dialyzed for 72 hours at 37 degrees C against a Sorensen's buffer solution using regenerated cellulose membranes having a molecular weight cutoff of 12 to 14 kDa. Additional protein-binding experiments were conducted to assess the potential PPB drug interactions between karentiecin and other highly protein-bound drugs commonly used in the treatment of cancer patients. "
|2.||Melanoma (Melanoma, Malignant)
11/01/2011 - "The authors review the data on karenitecin in preclinical models and in clinical trials in melanoma using studies published in Medline and reports presented at AACR and ASCO. "
04/15/2005 - "Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study."
11/01/2011 - "The treatment for melanoma is in rapid transition and genomic profiling is now an integral part, and hence the optimal use of karenitecin in melanoma should be re-evaluated with regard to specific mutational status."
11/01/2011 - "In adverse prognostic factor melanoma, karenitecin showed prolonged disease stabilization in 34% of patients. "
11/01/2011 - "Karenitecin shows activity in melanoma, both as a single agent and in combination. "
|3.||Central Nervous System Neoplasms
|4.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2008 - "Karenitecin is a well-tolerated topoisomerase compound but has minimal activity in extensively pretreated ovarian cancer with the dose-schedule employed."
05/01/2008 - "Karenitecin, an analog of topotecan with solubility and pharmacologic advantages, was tested in a phase II trial in previously treated patients with recurrent or persistent ovarian cancer. "
04/01/2008 - "In the neuroblastoma cell lines (SK-N-DZ; SK-N-SH) and the DAOY medulloblastoma cell line, the combination of karenitecin and mafosfamide were synergistic. "
04/01/2008 - "The purpose of this study was to determine the cytotoxic effects of karenitecin and mafosfamide in vitro against leukemia, medulloblastoma, and neuroblastoma cell lines. "
04/01/2008 - "Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines."
|2.||Histone Deacetylase Inhibitors
|3.||Valproic Acid (Valproate, Semisodium)
|7.||Type I DNA Topoisomerases (Topoisomerase I)
|8.||Type II DNA Topoisomerases (Topoisomerase II)
|10.||Carrier Proteins (Binding Protein)
|1.||Heterologous Transplantation (Xenotransplantation)